Benign gynecological diseases
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Women aged 18 to 79; 2. Patients diagnosed with benign gynecological diseases by histology or cytology (Endometriosis, adenomyosis, uterine fibroids, ovarian cysts, etc); 3. Patients who have written and signed the informed consent form and are eligible for follow-up; 4. Patients with acceptable liver and kidney functions; 5. Patients who are taking vitamin D and calcium supplements regularly.
Exclusion criteria
Exclusion criteria: 1. Currently pregnant patients; 2. Patients participating in other clinical trials; 3. Patients or their families refused to participate in the research or there was a serious shortage of original data; 4. Patients who have suffered from other aggressive malignant tumors within two years; 5. Patients who are undergoing radiotherapy, chemotherapy or hormone therapy; 6. Patients with severe autoimmune diseases or active infections; 7. Patients with serious psychological or mental disorders; 8. Patients with hereditary vitamin D metabolic disorders or calcium metabolism-related hereditary diseases; 9. Any other situation that the researchers consider may put the patients at risk or seriously affect the safety assessment of the patients or the interpretation of the results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of Life Score (WHOQOL-BREF); | — |
Secondary
| Measure | Time frame |
|---|---|
| 25(OH) D level;Bone mineral density;Adverse events (including various adverse reactions caused by the patient's own anti-tumor therapy as well as intake of vitamin D and calcium); | — |
Countries
China
Contacts
The First Affiliated Hospital of Chongqing Medical University